| Company Name: |
Shanghai Chaolan Chemical Technology Center
|
| Tel: |
021-QQ：65489617 15618227136 |
| Email: |
Sales@ATKchemical.com |
| Products Intro: |
Product Name:Rezvilutamide
CAS:1572045-62-5
Purity:98 Package:1G,5G,10G,50G,100G,500G
|
| Company Name: |
Guangzhou Younan Technology Co., Ltd
|
| Tel: |
020-82000279 18988941452 |
| Email: |
YN_research@163.com |
| Products Intro: |
Product Name:Rezvilutamide
CAS:1572045-62-5
Purity:0.98 Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Rezvilutamide
CAS:1572045-62-5
Purity:99.96% Package:1mg/RMB 743;5mg/RMB 1820;10mg/RMB 2650
|
Rezvilutamide manufacturers
- Rezvilutamide
-
- $173.00 / 5mg
-
2026-03-05
- CAS:1572045-62-5
- Min. Order:
- Purity: 99.96%
- Supply Ability: 10g
|
| | Rezvilutamide Basic information |
| Product Name: | Rezvilutamide | | Synonyms: | Benzonitrile, 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)-;Rezvilutamide;SHR3680;Zavegepant Impurity 12 | | CAS: | 1572045-62-5 | | MF: | C22H20F3N3O4S | | MW: | 479.47 | | EINECS: | | | Product Categories: | | | Mol File: | 1572045-62-5.mol |  |
| | Rezvilutamide Chemical Properties |
| Boiling point | 648.3±65.0 °C(Predicted) | | density | 1.50±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (208.56 mM; Need ultrasonic) | | form | Solid | | pka | 13.42±0.20(Predicted) | | color | White to off-white |
| | Rezvilutamide Usage And Synthesis |
| Uses | Rezvilutamide (SHR3680) is an orally active androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer[1][2]. | | References | [1] SangjunYoo, et al. New drugs in prostate cancer. Prostate International Volume 4, Issue 2, June 2016, Pages 37-42.
[2] Veronica Mollica, et al. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells. 2019 Jan 11;8(1):43. DOI:10.3390/cells8010043
[3] Dai T, et al., A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients. Br J Clin Pharmacol. 2023 Feb;89(2):874-886. DOI:10.1111/bcp.15528 |
| | Rezvilutamide Preparation Products And Raw materials |
|